Saura C. Sahu – författare

This book addresses all the current, up-to-date developments in this scientific discipline. Liver is the chief metabolizing site in the body, and thus, it is a major target organ for drug and chemical toxicity. Therefore, hepatotoxicity is an important endpoint in the safety evaluation of drugs and chemicals. Contributions from leading investigators in hepatotoxicity research address current developments in this scientific discipline and discuss use of current cutting edge technology such as microarrays in hepatotoxicity thus providing a better understanding of hepatotoxins, their interactions and mechanisms of action.This valuable authoritative source of information is the first book to address this topic for nearly ten years, making it an essential resource for readers from a wide range of disciplines such as toxicology, pharmacology, hepatology, drug toxicity and food science.

Toxicogenomics is the integration of genomics to toxicology. This technology is a powerful tool for collecting information from a large number of biological samples simultaneously and thus it is very useful for large-scale screening of potential toxicants. Toxicogenomics: A Powerful Tool For Toxicity Assessment provides up-to-date state-of-the-art information presented by the recognized experts, and is therefore an authoritative source of current knowledge in this field of research. The potential link between toxicology, genetics and human diseases makes this book very useful to investigators in many and varied disciplines of science and toxicology. Topics covered include: mechanistic toxicogenomicsanalysis and interpretation of toxicogenomic dataprinciples of data mining in toxicogenomicsdesign issues in toxicogenomics studiessources of variability in toxicogenomic assaysEscherichia coli stress response as a tool for detection of toxicitytoxicogenomics as a tool to assess immunotoxicitytoxicogenomics and ecogenomics for studying endocrine disruption and basic biologyuse of toxicogenomics as an early predictive tool for hepatotoxicitynutrigenomics: the application of genomic signatures in nutrition-related researchapplication of toxicogenomics in drug discoverypotential uses of toxicogenomic biomarkers in occupational health and risk assessmentusefulness of toxicogenomics in the regulatory environmentperspectives on toxicogenomics at the US Environmental Protection AgencyToxicogenomics: A Powerful Tool For Toxicity Assessment   is an essential resource for research scientists currently engaged in toxicogenomics, and will also be of interest to researchers working in toxicology, genetics, medicine, pharmacology, and food sciences, and to regulators and risk assessors of drug, food, environmental and agricultural products.

Nanomaterials - substances smaller than 100 nanometers in size - have been added in recent years to an increasing numbers of consumer products used in day-to-day life; in food packaging, medical devices, pharmaceuticals, cosmetics, odor-resistant textiles and household appliances. The extensive application of nanomaterials in a wide range of products for human use poses a potential for toxicity risk to human health and the environment. Such adverse effects of nanomaterials on human health have triggered the development of a new scientific discipline known as “nanotoxicity” – the study of the toxicity of nanomaterials. Nanotoxicity: From in vivo and in vitro Models to Health Risks provides up-to-date state-of-the-art information presented by recognized experts in this emerging new field in toxicology. It discusses the safety evaluation of nanomaterials in foods, drugs, medical devices, cosmetics and other regulated products and its use in risk analysis for potential regulatory use. Topics covered include: biomarkers for nanotoxicity assessmentnanotoxicity assessment by gene expression analysisin vivo and in vitro models for nanotoxicity testingmechanisms of nanotoxicitypharmakokinetics of nanomaterialsnanotoxicity of foods including food processing, food packaging and food safetynanotoxicity of drugs including drug development and drug deliverynanotoxicity of cosmetics and consumer productshealth and environmental impact of nanotoxicitysafety evaluation of nanomaterialsregulatory impact of nanomaterialsNanotoxicity: From in vivo and in vitro Models to Health Risks is a valuable authoritative source of information for readers from a wide range of disciplines such as toxicology, pharmacology, drug toxicity and food and environmental sciences. The book will be useful to the research community in academia, industry, hospitals and government, as well as to government regulators and risk assessors of foods, drugs and environmental and agricultural products.

Frontiers in Toxicology is the essential tool for toxicologists and pharmacologists working in academia, industry and regulatory bodies looking to stay at the forefront of three of the most important and upcoming areas of toxicology: toxicogenomics, hepatotoxicity and nanotoxicity. Insights from leading researchers into the current trends and future directions of research are presented in three volumes.  Each volume provides details on recent scientific discoveries, rules of best practice and addresses how national and international regulatory agencies will deal with the safety issues associated with toxicology.  Many of the chapters are written by authors working for the US Food and Drug Administration, including Dr. Saura C. Sahu himself.Titles included in the three volume set:Nanotoxicity: From In Vivo and In Vitro Models to Health Risks  - August 2009Toxicogenomics: A Powerful Tool for Toxicity Assessment - October 2008Hepatotoxicity: From Genomics to In Vitro and In Vivo Models - December 2007Each volume is also available to purchase individually.

During the past decade it has become evident that microRNAs regulate gene expressions and control many developmental and cellular processes in eukaryotic organisms. Recent studies suggest that microRNAs play an important role in toxicogenomics and are likely to play an important role in a range of human diseases including cancer. microRNAs in Toxicology and Medicine is a comprehensive and authoritative compilation of up-to-date developments in this emerging research area, presented by internationally recognized investigators. It focuses on the role of microRNA in biology and medicine with a special emphasis on toxicology. Divided into six parts, topics covered include: microRNA and toxicology – including environmental toxicants and perturbation of miRNA signaling; microRNA, and Disease States featuring microRNAs in drug-induced liver toxicity, microRNAs and Inflammation the regulatory role of microRNA in mutagenesis, microRNAs and cancer, and the role of microRNAs in tumor progression and therapy, as well as current understanding of microRNAs as therapeutic targets in cancermicroRNAs and disease statesmicroRNAs and stem cellsmicroRNAs and genomicsmicroRNAs and epigenomicsmicroRNAs and biomarkers – including body fluid microRNAs as toxicological biomarkers, cell-free microRNAs as biomarkers in human diseases, and circulating microRNAs as biomarkers of drug-induced pancreatitismicroRNAs in Toxicology and Medicine is an essential insight into the current trends and future directions of research in this rapidly expanding field for investigators, toxicologists, risk assessors, and regulators in academia, medical settings, industry, and government.

The Handbook of Nanotoxicology, Nanomedicine and Stem Cell Use in Toxicology provides an insight into the current trends and future directions of research in these rapidly developing scientific fields. Written by leading scientists and experts, the Handbook will be of interest to various scientific disciplines including toxicology, medicine, and pharmacology, as well as food, drug, and other regulatory sciences.

A comprehensive and authoritative compilation of up-to-date developments in stem cell research and its use in toxicology and medicine Presented by internationally recognized investigators in this exciting field of scientific researchProvides an insight into the current trends and future directions of research in this rapidly developing new fieldA valuable and excellent source of authoritative and up-to-date information for researchers, toxicologists, drug industry, risk assessors and regulators in academia, industry and government

Genomic and Epigenomic Biomarkers of Toxicology and Disease The latest developments in biomarker research applicable to toxicology and medicine Research on genomic and epigenomic biomarkers is developing rapidly with cutting-edge studies scattered throughout the academic literature, making the status of ongoing scientific activity in this area difficult to ascertain. Genomic and Epigenomic Biomarkers of Toxicology and Disease: Clinical and Therapeutic Actions delivers a comprehensive and authoritative compilation of up-to-date developments in the application of genomic and epigenomic biomarkers to toxicology, disease prevention, cancer detection, therapeutics, gene therapy, and other areas. With contributions from a collection of internationally recognized investigators, this edited volume offers unique insights into current trends and future directions of research in the discussed areas. Combining state-of-the-art information on genomic and epigenomic biomarkers from a range of specialists from around the world, this monograph includes: A thorough introduction to microRNAs as non-invasive biomarkers of toxicity and chemical hazardComprehensive explorations of extracellular vesicle-associated miRNAs as toxic biomarkers, as well as transcriptomic applications in toxicology and medicinePractical discussions of circulating miRNAs as biomarkers of metal exposure, as well as microRNAs biomarkers of malignant mesotheliomaIn-depth examinations of the role of noncoding RNAs in innate immune responses perturbed by environmental arsenic with a focus on microRNAsPerfect for researchers, toxicologists, risk assessors, and regulators, Genomic and Epigenomic Biomarkers of Toxicology and Disease: Clinical and Therapeutic Actions will also earn a place in the libraries of graduate students with an interest in biomarkers, toxicology, agriculture, or the environment.

Impact of Engineered Nanomaterials in Genomics and Epigenomics Overview of current research and technologies in nanomaterial science as applied to omics science at the single cell level Impact of Engineered Nanomaterials in Genomics and Epigenomics is a comprehensive and authoritative compilation of the genetic processes and instructions that specifically direct individual genes to turn on or off, focusing on the developing technologies of engineering nanomaterials and their role in cell engineering which have become important research tools for pharmaceutical, biological, medical, and toxicological studies. Combining state-of-the art information on the impact of engineered nanomaterials in genomics and epigenomics, from a range of internationally recognized investigators from around the world, this edited volume offers unique insights into the current trends and future directions of research in this scientific field. Impact of Engineered Nanomaterials in Genomics and Epigenomics includes detailed information on sample topics such as: Impact of engineered nanomaterials in genomics and epigenomics, including adverse impact on glucose energy metabolismToxicogenomics, toxicoepigenomics, genotoxicity and epigenotoxicity, and mechanisms of toxicogenomics and toxicoepigenomicsAdverse effects of engineered nanomaterials on human environment and metabolomics pathways leading to ecological toxicityMeta-analysis methods to identify genomic toxicity mechanisms of engineered nanomaterials and biological effects of engineered nanomaterial exposureArtificial intelligence and machine learning of single-cell transcriptomics of engineered nanoparticles and trends in plant nano-interaction to mitigate abiotic stressesThis comprehensive work is a valuable and excellent source of authoritative and up-to-date information for advanced students and researchers, toxicologists, the drug industry, risk assessors and regulators in academia, industry, and government, as well as for clinical scientists working in hospital and clinical environments.